ClinicalTrials.gg
CompletedNCT03596385Updated Jun 6, 2025

TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion"

A Phase 4 interventional study of Beta blocker in Myocardial Infarction, sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. Completed at 111 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
8,505
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing Beta blockers in Myocardial Infarction — 3 open to participants now, 3 under way, none of them phase 3. A drug class: Beta blockers · Myocardial Infarction.

Started
2018
with 1 other
Phase 4
7 of 10
2 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Among the 10 studies testing Beta blockers in Myocardial Infarction, this one is one of 2 that started in 2018, is one of 7 in phase 4, and was the 6th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

3 of the 10 studies testing Beta blockers in Myocardial Infarction are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Beta blockers

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Beta blockers in Myocardial Infarction, or all of them as a file.
02

Study summary

REBOOT clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. Half of the participants will be randomized to receive long-term beta-blocker therapy and the other half to no beta-blocker therapy after hospital discharge. All patients will be followed up for up to 5 years to determine the occurrence of adverse events (all cause mortality, re-infarction, and heart failure admission).

Read the detailed description

Pragmatic, controlled, prospective, randomized, open-label, blinded endpoint clinical trial testing the benefits of beta-blocker maintenance therapy in patients discharged after an acute myocardial infarction (MI). Patients being discharged after an acute MI, with or without ST-segment elevation, and with a left ventricular ejection fraction >40%, and without history of heart failure (HF) prior to study inclusion, will be recruited. At discharge, patients will be randomized (1:1) to receive beta-blocker therapy (agent and dose according to treating physician) or no beta-blocker therapy. Primary outcome is the 5 years incidence of MACE (all cause mortality, reinfarction, heart failure admission).

03

Conditions studied

  • Myocardial Infarction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years old
  • Admitted for STEMI or NSTEMI and invasive management (i.e. coronary angiography during index hospitalization).
  • >40% as evaluated by any imaging technique anytime during hospitalization.
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Known allergy or intolerance to beta-blockers
  • Absolute to beta-blocker therapy according to treating physician judge
  • Prior history of HF, Killip class on admission or during hospitalization ≥ II
  • Severe valvular heart disease (> 3+ for aortic or mitral insufficiency, aortic or mitral valve area ≤1.0 cm2).
  • Any condition (appart from AMI) that requires beta-blocker prescription on discharge according to treating physician judge
  • Any medical condition that, in the investigator´s judgment, would seriously limit (less than one year),
  • Patients participating in other clinical trials
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8,505 participants (actual)

Study arms

  • Experimental
    Beta-blocker therapy

    This is a strategy (pragmatic) trial. In patients allocated to "Beta-blocker therapy", beta blocker agent and dose are decided by treating physician. betablocker therapy chosen might be any of the following: atenolol bisoprolol carvedilol metoprolol nebivolol

    Drug: Beta blocker

  • No intervention
    Control (no beta-blocker therapy).

    Do not receive beta -blocker therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence rate of the composite of "all-cause death, nonfatal reinfarction, or heart failure hospitalization" (MACE)

    absolute number of patients experiencing deaths will be added to number of patients experiencing a non fatal reinfarction and to number of patients experiencing heart failure hospitalization. If a patient experience more than one of these events, only first event will be added for the sum of events EXAMPLE events in arm 1: 150 deaths+150 reinfarctions+150 heart failure hospitalizations= TOTAL 450 MACE (450 events/4234 patients enroled: event rate 10.63%)

    Time frame: 12-54 months since the beginning (median follow up anticipated 3.75 years)

Secondary outcomes

  1. 2.1 Incidence rate of individual components of the primary outcome. 2.2 Incidence rate of cardiac mortality. 2.3 Incidence of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) and resuscitated cardiac arrest.

    Absolute number of events (% from total patients recruited) of the components of the MACE (eg number of all cause deaths (% from patients included) in active arm vs control). First event of each individual component counts for secondary outcome. EXAMPLE all cause death events in in arm 1: 200 deaths (200 events/4234 patients enroled: event rate 4.72%). nonfatal reinfarctions in in arm 1: 150 reinfarctions (150 events/4234 patients enroled: event rate 3.54%). note that in the example of the primary outcome, only 150 deaths are counted and for the secondary outcome 200. This is because in this hypothetical case, 50 deaths occurred in patients who previously experienced a nonfatal reinfarction

    Time frame: 12-54 months since the beginning (median follow up anticipated 3.75 years)

Other outcomes

  1. 3.1 Incidence of revascularizations during follow-up 3.2 Composite of cardiac death, stroke or myocardial infarction. 3.3 Safety endpoints 3.4 Quality of life and functional status (telephone evaluation):

    3.1: Absolute number of patients undergoing a revascularization procedure during follow-up (% from total patients recruited) note: revascularizations that were scheduled at patients' discharge inclusion WILL NOT be considered an event 3.2: absolute number of patients experiencing cardiac death will be added to number of patients experiencing a stroke and to number of patient experiencing a non fatal reinfarction. If a patient experience more than one of these events, only first event will be added for the sum of events 3.3 3.3.1: Incidence of admission for symptomatic advanced atrioventricular (AV) block (Mobitz II or third degree). Absolute number of patients admitted for symptomatic AV block (% from total patients recruited) 3.3.2: Incidence of hospital admission for stroke: Absolute number of patients admitted for a stroke during follow-up (% from total patients recruited) 3.4 EQ-5D questionnaire (0-100, 100 best) IIEF-5 quest (5-25, 25 best) PHQ-2 questionnaire (0-6, 6 worst)

    Time frame: 12-54 months since the beginning (median follow up anticipated 3.75 years)

07

Study locations

111 sites
  • Teresa Masselli Mascia
    San Severo, Foggia, Italy
  • Ospedale Civile Santi Antonio e Biagio
    Alessandria, Italy
  • Azienda Ospedaliero Universitaria Ospedali Riuniti
    Ancona, Italy
  • Ospedale Civile
    Baggiovara, Italy
  • Istituto Maugeri IRCCS
    Bari, Italy
  • Ospedale San Paolo
    Bari, Italy
  • Ospedale Maggiore
    Bologna, Italy
  • A.O. Sant'Anna e San Sebastiano di Caserta
    Caserta, Italy
  • Santa Margherita
    Cortona, Italy
  • Ospedale di Cremona
    Cremona, Italy
  • Ospedale di Desio
    Desio, Italy
  • Ospedale San Giuseppe
    Empoli, Italy
  • Ospedale di Vaio
    Fidenza, Italy
  • Azienda Ospedaliera Universitaria - Ospedali Riuniti Foggia
    Foggia, Italy
  • Ospedale C.G.Morgagni
    Forlì, Italy
  • Ospedale Misericordia
    Grosseto, Italy
  • Ospedale Gualdo Tadino
    Gubbio, Italy
  • Ospedale Civile di Legnano
    Legnano, Italy
  • Ospedale di Vizzolo Predabissi
    Melegnano, Italy
  • Mario Negri
    Milano, Italy
  • Ospedale San Paolo
    Milano, Italy
  • Ospedale Sacro Cuore Don Calabria
    Negrar, Italy
  • Ospedale San Luigi Gonzaga
    Orbassano, Italy
  • Policlinico San Marco
    Osio Sotto, Italy
  • Villa Sofía, Palermo
    Palermo, Italy
  • P.O. di Passirana
    Passirana, Italy
  • Ospedale G. da Saliceto ,Piacenza
    Piacenza, Italy
  • Ospedalel Santa Maria delle Croci
    Ravenna, Italy
  • Arcispedale S. Maria Nuova
    Reggio Emilia, Italy
  • Ospedale Infermi di Rimini
    Rimini, Italy
  • San Filippo Neri
    Roma, Italy
  • Presidio Ospedaliero di Saronno
    Saronno, Italy
  • Ospedale Veris Delli Ponti
    Scorrano, Italy
  • Ospedale Bolognini
    Seriate, Italy
  • Ospedale di Treviglio
    Treviglio, Italy
  • Ospedale di Udine
    Udine, Italy
  • Txagorritxu
    Alava, Spain
  • Fundacion Alcorcon
    Alcorcón, Spain
  • Virgen de los Lirios de Alcoy
    Alcoy, Spain
  • H. San Juan
    Alicante, Spain
  • Hospital Alto del Gualdalquivir
    Andújar, Spain
  • San Agustin
    Avilés, Spain
  • Centro Medico Teknon
    Barcelona, Spain
  • Clinic
    Barcelona, Spain
  • Consorci Sanitari Integral
    Barcelona, Spain
  • Germans Trias i Pujol
    Barcelona, Spain
  • H. Vall d´Hebron
    Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitario de Bellvitge
    Barcelona, Spain
  • Hospital de Basurto
    Bilbao, Spain
  • Hospital Universitario de Burgos
    Burgos, Spain
  • H. Santa Lucía
    Cartagena, Spain
  • Hosptial Universitario Reina Sofia
    Córdoba, Spain
  • Hospital de Denia
    Denia, Spain
  • Hospital universitario de Elche
    Elche, Spain
  • Hospital Universitario de Vinalopo
    Elche, Spain
  • H.Universitario de Elda
    Elda, Spain
  • Hospital Arquitecto Macide
    Ferrol, Spain
  • Hospital Galdakao Usansolo
    Galdakao, Spain
  • Cabueñes
    Gijón, Spain
  • Hospital San Cecilio
    Granada, Spain
  • Hospital Virgen de las Nieves
    Granada, Spain
  • H.U Juan Ramón Jimenez
    Huelva, Spain
  • Complejo Hospitalario Universitario de Jaen
    Jaén, Spain
  • Complejo hospitalario universitario a Coruña
    La Coruña, Spain
  • Complejo Hospitalario Universitario Insular Materno Infantil
    Las Palmas De Gran Canaria, Spain
  • Hospital Universitario de Arnau de Vilanova
    Lerida, Spain
  • Hospital de Leon
    León, Spain
  • Lucus Augusti
    Lugo, Spain
  • Fundación Jiménez Díaz University Hospital
    Madrid, 28040, Spain
  • Clinica La Luz
    Madrid, Spain
  • CNIC
    Madrid, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
  • Hospital Clinico
    Madrid, Spain
  • Hospital Gregorio Marañon
    Madrid, Spain
  • Hospital Quirón Pozuelo
    Madrid, Spain
  • Ruber Internacional
    Madrid, Spain
  • Ruber Juan Bravo
    Madrid, Spain
  • Hospital de Manresa
    Manresa, Spain
  • Hospital Alvarez Buylla
    Mieres, Spain
  • Hospital Clinico Universitario Virgen de la Arrixaca
    Murcia, Spain
  • Hospital regional Universitario de Malaga
    Málaga, Spain
  • Rey Juan Carlos
    Móstoles, Spain
  • Hospital Universitario Central Asturias
    Oviedo, Spain
  • Son Espases
    Palma De Mallorca, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, Spain
  • Montecelo
    Pontevedra, Spain
  • Clinico Universitario de Salamanca
    Salamanca, Spain
  • Marques de Valdecilla
    Santander, Spain
  • Complejo hospitalario universitario de Santiago
    Santiago De Compostela, Spain
  • H. Virgen del Rocio
    Sevilla, Spain
  • Virgen de la Macarena
    Sevilla, Spain
  • Hospital Universitari Joan XXIII
    Tarragona, Spain
  • Hospital Universitario Sant Joan de Reus
    Tarragona, Spain
  • Complejo hospitalario Universitario de Canarias
    Tenerife, Spain
  • Hospital General de La Palma
    Tenerife, Spain
  • Nuestra Señora de la Candelaria
    Tenerife, Spain
  • Hospital Universitario de Torrejon
    Torrejón De Ardoz, Spain
  • Hospital Universitario de Torrevieja
    Torrevieja, Spain
  • H. Verge de la Cinta
    Tortosa, Spain

Showing the first 100 of 111 sites across 2 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabes JA, Sanchez PL, Anguita M, Fernandez-Vazquez F, Pascual-Figal D, De la Torre Hernandez JM, Ferraro S, Vetrano A, Perez-Rivera JA, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Aguero J, Pocock S, Ottani F, Fuster V, Ibanez B; REBOOT-CNIC investigators. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):291-301. doi: 10.1093/ehjcvp/pvab060. PubMed 34351426 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Jan 2025, 75 months.

Of 83 non-industry phase 4 interventional studies under Myocardial Infarction, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 78. This study's 75 months is above that.

Counting every sponsor, half of 87 studies reached it within 42 months; a quarter within 22 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2018
First posted
Jul 23, 2018
StartActual
Oct 31, 2018
Primary completionActual
Jan 31, 2025
CompletionActual
Jan 31, 2025
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03596385
Lead sponsor
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Responsible party
Sponsor
First posted
Jul 23, 2018
Start date
Oct 31, 2018
Primary completion
Jan 31, 2025
Completion
Jan 31, 2025
Last update
Jun 6, 2025

Study contacts

Borja Ibañez, MD PhD FESC
principal investigator · CNIC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beta blockers

Start the discussion